Kandoth C, Schultz N, Chemiack AD, et al. Integrated genomic characterization of endometrial carcinoma[ J]. Nature,2013,497(7447):67 -73.
Meng B,Hoang L N,McIntyre J B, et al.POLE exonuclease domain mutation predicts long progression free survival in grade 3 endometrioid carcinoma of the endometrium[J].Gynecol Oncol,2014,134(1):15-19.
León-Castillo A,et al.(2020). Trans PORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer:Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol.
Bellone S,Bignotti E,Lonardi S,et al. Polymerase ε(POLE) ultramutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro[J]. Gynecol Oncol,2017,144(1):146-152.
Talhouk A, Mcalpine JN. New classification of endometrial cancers:the development and potential applications of genomic-based classification in research and clinical care [ J ]. Gynecol Oncol Res Pract, 2016,3(1):14.
Church D N,StellooE, Nout R A, et al. Prognostic significance of POLE proof reading mutation sin endometrial cancer [J]. J Natl Cancer Inst ,2015,107(1):402.
Talhouk A, Mcconechy M K, Leung S, et al. Confirmation of ProMisE :A simple, genomics-based clinical classifier for endometrial cancer[J]. Cancer,2017,123(5):802-813.
孙丽丽,刘格丹,贾楠,等. 不同分子分型的子宫内膜癌临床病理特征分析[J]. 肿瘤预防与治疗,2022,35(5):435-441.
Talhouk A, Mcconechy M K, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers[J]. Cancer,2015,113(2):299-310.